Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Susanne Hultsch"'
Autor:
Susanne Hultsch, Matti Kankainen, Lassi Paavolainen, Ruusu-Maaria Kovanen, Elina Ikonen, Sara Kangaspeska, Vilja Pietiäinen, Olli Kallioniemi
Publikováno v:
BMC Cancer, Vol 18, Iss 1, Pp 1-14 (2018)
Abstract Background Tamoxifen treatment of estrogen receptor (ER)-positive breast cancer reduces mortality by 31%. However, over half of advanced ER-positive breast cancers are intrinsically resistant to tamoxifen and about 40% will acquire the resis
Externí odkaz:
https://doaj.org/article/c213cddea43e4757ba932cf82fd12a67
Autor:
Sara Kangaspeska, Susanne Hultsch, Henrik Edgren, Daniel Nicorici, Astrid Murumägi, Olli Kallioniemi
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e48745 (2012)
RNA-sequencing and tailored bioinformatic methodologies have paved the way for identification of expressed fusion genes from the chaotic genomes of solid tumors. We have recently successfully exploited RNA-sequencing for the discovery of 24 novel fus
Externí odkaz:
https://doaj.org/article/56bbb7de650e4363bb668164fde7d365
Autor:
Roy Zvi Granit, Evandro de Azambuja, Giancarlo Pruneri, Amir Sonnenblick, Nadia Harbeck, Christos Sotiriou, Dominique Agbor-Tarh, Ibrahim Fahoum, Alvaro Moreno-Aspita, Miguel Izquierdo, Minetta C. Liu, Martine Piccart, Susanne Hultsch, Ghizlane Rouas
Publikováno v:
International journal of cancer
The JAK/STAT3 signaling pathway may be aberrantly activated and have various and conflicting roles in breast cancer. The current study explored prognostic implications of activated STAT3 in human epidermal growth factor receptor 2 (HER2)-positive pri
Autor:
Guilherme Nader-Marta, Véronique Debien, Daniel Eiger, Zoi Tsourti, Rafael Caparica, Marie Kassapian, Sylvia Napoleone, Susanne Hultsch, Larissa Korde, Yingbo Wang, Saranya Chumsri, Kathleen I. Pritchard, Michael Untch, Meritxell Bellet-Ezquerra, Daniela Dornelles Rosa, Alvaro Moreno-Aspitia, Martine Piccart, Urania Dafni, Evandro de Azambuja
Publikováno v:
British journal of cancer. 127(10)
Patients with small node-negative HER2-positive breast cancer are commonly treated with paclitaxel and 1 year of adjuvant trastuzumab. We performed a sub-analysis of the ALTTO trial to explore the long-term outcomes of patients with small node-negati
Autor:
Tero Aittokallio, Alok Jaiswal, Olli Kallioniemi, John Patrick Mpindi, Samuli Eldfors, Henrik Edgren, Sara Kangaspeska, Susanne Hultsch, Oscar Brück
Publikováno v:
BMC Cancer
Background The estrogen receptor (ER) inhibitor tamoxifen reduces breast cancer mortality by 31 % and has served as the standard treatment for ER-positive breast cancers for decades. However, 50 % of advanced ER-positive cancers display de novo resis
Publikováno v:
Cancer Research. 76:2935-2935
Tamoxifen, as a standard treatment of estrogen receptor (ER)-positive breast cancer, reduces breast cancer mortality by 31%. In 50% of advanced ER-positive cancers, however, de novo resistance exists and in 40% of patients with initial response acqui
Autor:
Olli Kallioniemi, Dimitry Bychkov, Yadav Bhagwan, John Patrick Mpindi, Krister Wennerberg, Susanne Hultsch, Astrid Murumägi, Kimmo Porkka, Sara Kangaspeska, Caroline A. Heckman, Disha Malani, Hirasawa Akira, Tero Aittokallio, Khalid Saeed, Päivi Östling
Publikováno v:
Cancer Research. 74:4184-4184
Most drug-testing approaches published so far focus on identifying a single drug that shows favorable response and is associated with a known cancer biomarker such as the drug Imatinib in BCR-ABL gene fusion positive cells. We developed and applied d